Target intelligence / Profile preview

Brevican core protein (BCAN)

Target
BCAN
Molecular classification
Proteoglycan, Extracellular matrix protein, Lectican family member, Other (GPI-anchor variant)
01

Overview

Brevican core protein is a secreted proteoglycan predominantly expressed in the central nervous system, encoded by the BCAN gene. It belongs to the lectican family, sharing structural features such as an Ig-like V-set domain, two link domains, an EGF-like domain, a C-type lectin domain, and a Sushi/CRP-like domain. Brevican plays essential roles in forming and maintaining perineuronal nets—specialized extracellular matrix structures that enwrap neurons—and contributes to synaptic stability and plasticity during brain development. It is mainly produced by astrocytes, oligodendrocytes, and neurons. The dominant isoform is secreted during brain development; expression increases following CNS injury. Aberrant glycosylation patterns are associated with high-grade gliomas but not with low-grade tumors or other neuropathologies. There are no approved drugs directly targeting brevican; however, it remains under investigation as both a potential biomarker for certain brain cancers and as a modulator of neural repair processes after injury.

Other names
BEHABBrevicanBCAN (gene symbol)Brevican core protein
02

Mechanism of action

No established drug mechanisms specifically targeting brevican; research is ongoing into modulators that may affect its function in the ECM and perineuronal nets.

03

Biological functions

Formation and maintenance of perineuronal netsStabilization of extracellular matrix in the central nervous systemRegulation of synaptic plasticity and brain developmentModulation of neuron-glia interactions
04

Disease associations

Neurodegenerative disease (potential role in Alzheimer’s prevention)Brain injury response/upregulation after CNS traumaGlioma progression, especially aggressive gliomas
05

Biomarkers

Under-glycosylated forms upregulated in aggressive glioma may serve as a biomarker for tumor aggressiveness, but not yet clinically validated.

Beyond the preview

Go deeper on Brevican core protein (BCAN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brevican core protein (BCAN).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call